Request for an Extension of the Transitional Period under Article 66.1 of the Trips Agreement for Least Developed Country Members With Respect to Pharmaceutical Products
Filename | Request-4WTO-Extension.pdf |
filesize | 22.77 kB |
Version | |
Date added | February 27, 2015 |
Downloaded | 1724 times |
Category | Reports |
slide_template | default |
post_grid_post_settings | a:14:{s:9:"post_skin";s:4:"flat";s:19:"custom_thumb_source";s:94:"https://www.cehurd.org/wp-content/plugins/post-grid/assets/frontend/css/images/placeholder.png";s:16:"thumb_custom_url";s:0:"";s:17:"font_awesome_icon";s:0:"";s:23:"font_awesome_icon_color";s:0:"";s:22:"font_awesome_icon_size";s:0:"";s:17:"custom_youtube_id";s:0:"";s:15:"custom_vimeo_id";s:0:"";s:21:"custom_dailymotion_id";s:0:"";s:14:"custom_mp3_url";s:0:"";s:20:"custom_soundcloud_id";s:0:"";s:16:"custom_video_MP4";s:0:"";s:16:"custom_video_OGV";s:0:"";s:17:"custom_video_WEBM";s:0:"";} |
The Joint United Nations Programme on HIV/AIDS (UNAIDS) has expressed concern that
“without extension of the transition period, access to antiretroviral therapy and other key
medicines in LDCs will face real challenges”4
and with “a real danger …progress that has been made to improve access to HIV-related medicines in these countries will be reversed”.